Document ID: chunk:federal_register_of_legislation:F2024L01513:clause:1_222
Version: federal_register_of_legislation:F2024L01513
Segment Type: clause
Provision Reference: sch 1 cl 222
Character Range: 2813–3658

222   Vaccine                                                            Abrysvo  Injection (0.5mL)  Each 0.5mL dose contains 120 µg of stabilised prefusion F proteins (60 µg  RSV-A and 60 µg  RSV-B antigens)    1 dose:
      respiratory syncytial virus (RSV) stabilised prefusion F subunit                                                                                                                                                 1.      at 28 to 36 weeks gestation; or
                                                                                                                                                                                                                       2.      after 36 weeks gestation, if vaccination is two weeks prior to birth.
      Circumstances
      Vaccine may be provided to a person who is pregnant